Tricyclic antidepressants (TCAs)

Article written and reviewed by Dr Luca Moretti

Tricyclic antidepressants, or TCAs, are drugs that historically played a central role in the treatment of major depression. They remain effective, but in contemporary practice are used less frequently as first choice treatments because newer antidepressants generally offer better tolerability and greater safety in overdose. They nevertheless retain an important role in patients who have not responded to or tolerated more manageable treatments, when there is a documented previous response to a tricyclic antidepressant or when a specific drug offers clinical advantages for a concomitant condition.

The name derives from the three ring chemical structure of many drugs in the class and does not imply complete pharmacological identity. Amitriptyline, imipramine, clomipramine, doxepin, nortriptyline and desipramine differ in the relative inhibition of serotonin and norepinephrine reuptake, anticholinergic activity, histamine and alpha1 adrenergic antagonism, metabolism, half life and toxicity. These differences become particularly relevant in older adults, patients with heart disease, those receiving multiple medications and patients at risk of overdose.

Their use therefore requires a more structured prescribing approach than many second generation antidepressants. Before treatment begins, cardiovascular comorbidities, blood pressure, concomitant medications, anticholinergic risk, seizure history, potential interactions and suicide risk should be assessed. Dose, titration and any plasma monitoring should refer to the specific drug rather than to a generic “tricyclic dose”.

Classification and mechanism of action

TCAs can be divided, in simplified terms, into tertiary amines and secondary amines. Amitriptyline, imipramine and clomipramine are tertiary amines; nortriptyline and desipramine are the respective demethylated metabolites of amitriptyline and imipramine and belong to the secondary amines. This distinction is useful because tertiary amines tend on average to have stronger serotonergic and anticholinergic components, whereas several secondary amines show greater noradrenergic predominance and less, though not absent, anticholinergic activity.

The main antidepressant mechanism consists of inhibition of the SERT and NET transporters, increasing serotonergic and noradrenergic transmission. The clinical effect, however, does not simply result from the immediate rise in monoamines: receptor adaptations and intracellular signaling changes that develop over time contribute to the therapeutic response. For this reason, acute pharmacological changes precede the full clinical response by days or weeks.

Clomipramine is among the TCAs with the most potent SERT inhibition and is particularly relevant in obsessive compulsive disorder, whereas desipramine and nortriptyline have relatively more noradrenergic profiles. These differences do not, however, justify diagnosing a presumed “serotonin deficiency” or “norepinephrine deficiency” from the symptom profile and selecting a drug on that basis. Selection remains clinical and probabilistic.

TCAs antagonize muscarinic receptors to varying degrees. This causes dry mouth, constipation, urinary retention, blurred vision, reduced sweating and possible cognitive effects. In older adults, anticholinergic burden can promote confusion, delirium, falls and worsening of preexisting cognitive disorders. Amitriptyline and other tertiary amines are generally more problematic in this respect than nortriptyline.

H1 antagonism contributes to sedation, increased appetite and weight gain; alpha1 adrenergic antagonism can cause orthostatic hypotension, dizziness and syncope. These effects may be clinically useful in some patients with insomnia, but should not be confused with the antidepressant mechanism or used to justify treatment when the risk of falls or hypotension is high.

The ability to block myocardial fast sodium channels is responsible for an important part of cardiotoxicity, especially in overdose. Slowing of ventricular depolarization can widen the QRS and predispose to arrhythmias; alpha1 inhibition and other effects contribute to hypotension. At therapeutic doses the risk is much lower, but becomes relevant in the presence of heart disease, conduction abnormalities, proarrhythmic combinations or excessive drug concentrations.

Their lipophilic structure and high protein binding promote a large volume of distribution. Many drugs are metabolized by CYP2D6 and CYP2C19, with substantial interindividual differences related to genetics, age, hepatic function and drug interactions. This contributes to variability among administered dose, plasma concentration and clinical effects.

Efficacy and indications in depression

Tricyclic antidepressants are effective in major depression. Comparisons with SSRIs and other antidepressants generally show modest differences in average efficacy, whereas tolerability and safety often favor newer drugs. For this reason, contemporary guidelines tend not to recommend TCAs as routine first choice treatment for uncomplicated depression, particularly when effective and better tolerated alternatives are available.

A TCA may be considered after an inadequate response to one or more appropriately used antidepressants, but “resistance” does not simply mean failure of a single prescription. Before changing class, diagnosis, adherence, treatment duration, dose, substance use, comorbidities, interactions and the presence of bipolar disorder should be reviewed. A previous personal response to a tricyclic antidepressant is an important clinical factor and may justify reusing it if no new risk factors have emerged.

TCAs have a long history of use in patients with severe or melancholic depression, but no diagnostic criterion automatically requires this class. In patients at high suicide risk, the greater toxicity in overdose weighs heavily in treatment selection: it may be necessary to prefer drugs that are less lethal in intentional ingestion, limit the amount dispensed and intensify monitoring.

Some TCAs also have indications or evidence in nondepressive conditions. Amitriptyline is used in some neuropathic pain syndromes and in the prevention of certain headaches, whereas clomipramine has an established role in obsessive compulsive disorder. These indications should not be used to attribute a generic analgesic or antiobsessional effect to the whole class: benefit is drug specific and should be distinguished from treatment of depression.

The presence of insomnia may make a sedating drug less disadvantageous, but marked sedation is not equivalent to antidepressant efficacy. Similarly, fatigue does not identify a patient who is destined to respond to a more noradrenergic drug. Symptom characteristics help anticipate tolerability and functional impact; they do not provide a pharmacological biomarker.

In psychotic depression, TCAs do not replace the need to treat the psychotic component; guidelines generally recommend an antidepressant antipsychotic combination or, in appropriate presentations, electroconvulsive therapy. In bipolar depression, tricyclic antidepressants require particular caution because of the risk of switching and are not a standard monotherapy choice.

In older adults, antidepressant efficacy must be balanced against a greater risk of hypotension, falls, urinary retention, constipation, confusion, arrhythmias and interactions. The Beers Criteria include several strongly anticholinergic antidepressants among potentially inappropriate medications in older adults. This does not mean that every TCA is absolutely prohibited after age 65, but it requires a clear clinical rationale and, whenever possible, selection of safer alternatives.

Dosage, pharmacokinetics and therapeutic drug monitoring

There is no initial or therapeutic dose that applies to the entire class. Dosage depends on the drug, indication, formulation, age and comorbidities. In depression, effective doses are generally higher than those often used for pain or insomnia. Gradual titration reduces hypotension, sedation and anticholinergic symptoms and makes it possible to identify poor tolerability early.

Evening administration is common for sedating drugs, but divided dosing or once daily administration depends on half life, formulation and tolerability. Lower starting doses and slower increases are generally used in older or frail patients. The principle “start low, go slow” should not, however, become permanently subtherapeutic treatment when the goal is an antidepressant effect.

Many TCAs undergo substantial first pass metabolism and produce pharmacologically active metabolites. Amitriptyline is converted to nortriptyline and imipramine to desipramine. Genetic differences in CYP2D6 and CYP2C19 can produce markedly different exposures at the same dose; enzyme inhibitors, inducers, liver disease and age related changes can also alter concentrations.

CPIC guidelines provide pharmacogenetic recommendations for several TCAs in relation to CYP2D6 and CYP2C19. Poor metabolizers can develop higher concentrations and adverse effects at standard doses, whereas ultrarapid metabolizers may achieve inadequate concentrations. These recommendations are useful when genotype is known, but do not imply that testing is mandatory in every patient.

Therapeutic drug monitoring can be particularly useful for tricyclic antidepressants with established reference ranges, especially in cases of nonresponse, unexpected adverse effects, suspected nonadherence, interactions, older age, pregnancy, liver disease or suspected atypical metabolism. Plasma values should be interpreted in relation to sampling time, stable dose and the clinical situation.

Nortriptyline has a historically well studied concentration response relationship, whereas for other TCAs monitoring is mainly a tool for safety and optimization. A concentration “within range” does not guarantee response, and a concentration outside the range does not replace clinical judgment. TDM is most useful when the clinical question is clearly defined: nonresponse, toxicity, interaction or uncertainty about adherence.

The time required to judge efficacy depends on dose adequacy and clinical course. A partial response may emerge during the first weeks, but remission often requires a longer period. If the patient does not improve, the diagnosis and actual exposure should be reassessed before exceeding dose limits or adding drugs.

Discontinuation should be gradual after prolonged treatment. Abrupt dose reduction can produce cholinergic rebound symptoms, gastrointestinal disturbances, insomnia, anxiety and malaise. Tapering is individualized and should be more cautious after long courses or in patients who have previously experienced discontinuation symptoms.

Adverse effects and clinical contraindications

The adverse effects of TCAs reflect their activity at multiple receptor systems. Muscarinic blockade causes anticholinergic effects, including dry mouth, constipation, urinary retention and blurred vision; in predisposed patients it can worsen uncontrolled angle closure glaucoma, urinary retention caused by obstruction and cognitive impairment. Severe constipation may progress to ileus, particularly in older people or those taking other anticholinergic drugs.

Alpha1 antagonism causes orthostatic hypotension, dizziness and syncope. Risk increases with dehydration, antihypertensive therapy, older age and autonomic neuropathy. Sedation from H1 antagonism can impair driving and work activities and increase fall risk, especially at the start of treatment or in combination with alcohol, benzodiazepines, opioids or other sedatives.

Weight gain is more common with strongly histaminergic drugs and can contribute to metabolic deterioration. Sexual dysfunction, sweating and tremor can interfere with adherence. Patients should be informed before treatment begins, because many adverse effects are otherwise reported late or lead to self initiated discontinuation.

Cardiovascular effects can include sinus tachycardia, hypotension, conduction abnormalities and prolongation of electrocardiographic intervals. Particularly careful assessment is required in patients with ischemic heart disease, heart failure, arrhythmias, conduction disorders or use of proarrhythmic drugs. A baseline ECG is indicated when age, history or concomitant treatment suggests risk, not identically in every healthy young adult.

TCAs can lower the seizure threshold, particularly at high concentrations. A history of uncontrolled epilepsy, brain lesions, alcohol misuse or concomitant drugs that lower seizure threshold requires caution. The onset of seizures during treatment requires urgent reassessment of dose, concentrations and possible concomitant causes.

Conditions that contraindicate or make use inadvisable vary among individual drugs and product information. Recent myocardial infarction, significant conduction abnormalities, concomitant MAOI use, severe urinary retention and some forms of glaucoma are examples of situations that may represent contraindications or strong precautions. It is incorrect to convert older age or suicidal ideation into “absolute class contraindications”, but both substantially alter the benefit risk balance.

During pregnancy, the decision should consider maternal and fetal risks, response history and alternatives; abruptly stopping an effective treatment without assessment is inappropriate. During breastfeeding, infant exposure and the profile of the individual drug should be examined separately. The category “tricyclic antidepressant” is not sufficient for a perinatal decision.

The most relevant interactions arise from additive anticholinergic, sedative, hypotensive and proarrhythmic effects and from inhibition or induction of metabolic enzymes. Fluoxetine, paroxetine and bupropion can increase exposure to TCAs metabolized by CYP2D6; combinations with other QT prolonging drugs require caution. Use with MAOIs can cause severe reactions and requires the washout periods specified for the individual agents.

Cardiotoxicity and overdose

Overdose toxicity is one of the major limitations of TCAs. Compared with many modern antidepressants, relatively small amounts can produce a potentially fatal syndrome. For this reason, the amount prescribed or dispensed should be considered particularly carefully in patients at risk of self harm, and choosing a TCA requires stronger justification when safer alternatives are available.

Blockade of myocardial fast sodium channels slows conduction and causes QRS widening. Tachycardia, hypotension, conduction blocks, ventricular arrhythmias and cardiac arrest can occur. Risk does not depend solely on serum concentration, which during acute intoxication is not a reliable indicator of cardiac severity.

Neurological toxicity includes agitation, delirium, coma and seizures. Anticholinergic effects can produce mydriasis, dry skin, urinary retention and hyperthermia, while hypotension results from a combination of alpha1 mediated vasodilation, myocardial depression and rhythm disturbances. Complications can evolve rapidly, making overdose a true toxicological emergency.

The electrocardiogram is central to the assessment of intoxication. QRS widening, terminal axis abnormalities and arrhythmias provide more useful information than plasma concentration alone. Hospital treatment includes support of vital functions and, when indicated, sodium bicarbonate for cardiotoxicity and QRS widening according to toxicology protocols.

Seizures and hypotension should be managed in a monitored setting. Some antiarrhythmic drugs can worsen sodium channel blockade and are inappropriate. Suspected ingestion of a significant amount of a TCA therefore requires urgent assessment even when the patient initially appears stable.

Differences in toxicity among individual drugs do not eliminate the class issue. Modern reviews confirm that TCAs remain substantially more problematic in overdose than SSRIs. This factor should weigh in outpatient prescribing, particularly when a patient lives alone, has a history of suicide attempts or has access to large quantities of medication.

Prevention is part of treatment safety: medication reconciliation, appropriate quantities dispensed, patient and family education when indicated, interaction review and close follow up during periods of instability reduce risk. The ability to measure plasma levels does not make a drug intrinsically safe in overdose.

Monitoring, special populations and practical management

Before treatment starts, it is appropriate to obtain a personal and family cardiovascular history and assess syncope, arrhythmias, glaucoma, urinary retention, epilepsy, severe constipation, alcohol and substance use and concomitant therapy. Weight, blood pressure and heart rate are basic clinical parameters; ECG and electrolytes are indicated when justified by the risk profile.

During titration, orthostatic hypotension, sedation, anticholinergic effects, heart rate, neurological symptoms and adherence should be monitored. Patients should be warned about the risk of impaired driving early in treatment and the additive effects of alcohol and sedatives. Severe constipation, urinary retention, syncope or palpitations require prompt reassessment.

In older patients it is prudent to reduce the overall anticholinergic burden and, if a TCA is genuinely necessary, to prefer relatively less anticholinergic drugs. Nortriptyline can nevertheless also cause hypotension, arrhythmias and falls. Polypharmacy increases both pharmacodynamic and pharmacokinetic risks and should be reviewed systematically.

In hepatic impairment, metabolism may be reduced and require lower doses or closer monitoring; renal impairment has variable effects on metabolite elimination. There is no single adjustment for “renal impairment with TCAs”: decisions should refer to the specific drug and its product information.

When a TCA is combined with other antidepressants, the objective and rationale should be clear. The combination can increase exposure and toxicity without guaranteeing greater efficacy. In particular, potent CYP2D6 inhibitors can rapidly increase tricyclic concentrations; when the combination is clinically necessary, dose reduction, ECG or TDM may be useful.

Switching from or to an MAOI requires specific washout periods to prevent serotonin syndrome or other severe reactions. Clomipramine, because of its potent serotonergic component, is particularly problematic in these combinations. Timing should not be remembered as a universal rule but checked in the product information for the two drugs involved.

Maintenance treatment, when a TCA has produced remission, should be continued for a period appropriate to relapse risk and then reassessed. A previous effective response is a strong argument for continuing the same drug, provided its safety profile remains acceptable. With aging or the development of heart disease, new interactions or cognitive decline, the benefit risk balance may change and require reassessment.

In summary, TCAs are not obsolete drugs, but effective antidepressants with high management complexity. Their value is greatest when they are selected for a precise clinical reason and managed with titration, monitoring and toxicity prevention proportionate to the individual's risk.

Summary table

Bibliography
1. Lam RW et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Can J Psychiatry. 69(9), 2024: 641-687.
2. Qaseem A et al. Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 176(2), 2023: 239-252.
3. Cipriani A et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 391(10128), 2018: 1357-1366.
4. Hicks JK et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update. Clin Pharmacol Ther. 102(1), 2017: 37-44.
5. Hiemke C et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 51(1-2), 2018: 9-62.
6. Taylor D et al. The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use. Ther Adv Psychopharmacol. 14, 2024: 20451253241243297.
7. Thanacoody HKR et al. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 24(3), 2005: 205-214.
8. MacGillivray S et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 326(7397), 2003: 1014.
9. Tedeschini E et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 72(12), 2011: 1660-1668.
10. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 71(7), 2023: 2052-2081.
11. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 58(1), 2000: 19-36.
12. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline NG222, 2022, current review consulted on August 19, 2026.